11/10/2026
Over 50% of late-stage cancers are still driver negative (Attalla et al., 2021).
That's not a small gap in the catalog — it's a signal that we're missing important biology. A lot of it comes down to two factors:
1. Standard short-read NGS struggles to detect large structural variants (SVs).
2. FFPE samples are the most abundant resource in cancer research, yet nucleic acid degradation makes them challenging for most genomic assays.
Dovetail FFPE Assay changes the math by using linked-read sequencing technology to generate libraries that leverage both breakpoint-spanning and breakpoint-flanking reads thereby expanding the detection window to megabase-scale regions and significantly boosting sensitivity - all on standard short-read sequencers. No specialized equipment required.
The result: a comprehensive single-assay solution for FFPE tumor profiling that fits your existing NGS infrastructure.
Learn More: https://na2.hubs.ly/H08Vpxk0